Financial Comparison: Intelligent Bio Solutions (NASDAQ:INBS) & Nephros (NASDAQ:NEPH)

Nephros (NASDAQ:NEPH) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Nephros has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.63, indicating that its share price is 363% more volatile than the S&P 500.

Institutional and Insider Ownership

41.1% of Nephros shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 4.1% of Nephros shares are owned by insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Nephros and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nephros	-6.86%	-11.39%	-8.30%
Intelligent Bio Solutions	-323.79%	-146.03%	-83.62%

Earnings & Valuation

This table compares Nephros and Intelligent Bio Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$14.16 million	1.47	-$1.58 million	($0.09)	-21.77
Intelligent Bio Solutions	$3.03 million	2.66	-$10.16 million	N/A	N/A

Nephros has higher revenue and earnings than Intelligent Bio Solutions.

Analyst Ratings

This is a summary of current ratings for Nephros and Intelligent Bio Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0	0	1	0	3.00
Intelligent Bio Solutions	0	0	0	0	0.00

Nephros currently has a consensus price target of $5.00, indicating a potential upside of 155.23%. Given Nephros’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Nephros is more favorable than Intelligent Bio Solutions.

Summary

Nephros beats Intelligent Bio Solutions on 10 of the 12 factors compared between the two stocks.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.